The TBL1XR1 antibody is a research tool designed to detect Transducin Beta-Like 1 X-Linked Receptor 1 (TBL1XR1), a protein encoded by the *TBL1XR1* gene. TBL1XR1 is a core component of the nuclear receptor corepressor (N-CoR)/histone deacetylase 3 (HDAC3) complex, which regulates transcriptional repression and chromatin remodeling. Structurally, TBL1XR1 contains WD40 repeat domains that mediate protein-protein interactions, facilitating its role in nuclear receptor signaling and Wnt/β-catenin pathway modulation.
Antibodies targeting TBL1XR1 are widely used in studies investigating its expression patterns, subcellular localization, and functional interactions. They are validated in applications like Western blotting, immunoprecipitation, and immunofluorescence. Research has linked TBL1XR1 dysregulation to various diseases, including cancers (e.g., glioblastoma, breast cancer), neurodevelopmental disorders (e.g., autism, intellectual disability), and chemotherapy resistance. Epitope-tagged or monoclonal TBL1XR1 antibodies are often employed to ensure specificity, with validation via knockout cell lines or siRNA knockdown.
These antibodies have advanced understanding of TBL1XR1’s dual roles as a transcriptional coregulator and oncogenic driver, highlighting its potential as a biomarker or therapeutic target. Studies also explore its involvement in developmental pathways and drug response mechanisms, underscoring its broad biological relevance.